Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.

NCT05323890 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Advanced Esophageal Squamous Cell Cancer

Interventions

DRUG: Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy

Sponsor

Shandong Cancer Hospital and Institute